Tuesday, July 30, 2019 11:07:47 PM
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
15.61K 07/15/19 (Short Interest)
P/E Current
-1.52
P/E Ratio (with extraordinary items)
-1.63
Average Recommendation: BUY
Average Target Price: 13.50
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent ALPN News
- Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm • PR Newswire (US) • 04/11/2024 08:27:00 PM
- Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News • IH Market News • 04/11/2024 11:24:54 AM
- Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy • Business Wire • 04/10/2024 08:15:00 PM
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences • Business Wire • 04/10/2024 08:01:00 PM
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences • Business Wire • 04/10/2024 08:01:00 PM
- Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024 • Business Wire • 04/01/2024 01:00:00 PM
- Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 • Business Wire • 03/21/2024 11:45:00 AM
- Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference • Business Wire • 03/20/2024 08:30:00 PM
- Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results • Business Wire • 03/18/2024 08:05:00 PM
- Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:30:00 PM
- Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences • Business Wire • 02/26/2024 09:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:43:28 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:22:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:12:02 PM
- Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences • Business Wire • 02/01/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 11:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 11:08:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 11:06:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:45:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 12:06:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 12:05:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:23:56 PM
- Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie • Business Wire • 12/21/2023 09:15:00 PM
- Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/18/2023 09:30:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/22/2023 03:25:55 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM